Use NF-κB inhibition in combination therapy for cancer
First Claim
Patent Images
1. A method of enhancing the cytotoxic effects of an antineoplastic chemotherapeutic agent, comprising administering to a mammalian subject in need of said antineoplastic chemotherapeutic agent a therapeutically effective amount of NF-κ
- B inhibitor in conjunction with the administration of a dosage of the chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent is increased compared to that which would occur in the absence of NF-κ
B inhibitor,wherein said NF-κ
B inhibitor is a proteasome inhibitor,wherein the dosage of said antineoplastic chemotherapeutic agent is decreased as compared to a dosage effective without administering the NF-κ
B inhibitor in conjunction with the administration of the chemotherapeutic agent,and wherein said subject is afflicted with lung, breast, prostate, brain, kidney, liver, spleen, pancreas, bone or muscle cancer, leukemia or lymphoma, a sarcoma, a carcinoma or a mixed tumor.
4 Assignments
0 Petitions
Accused Products
Abstract
The use of NF-κB inhibitors to enhance the cytotoxic effects of chemotherapy or radiation therapy in the treatment of neoplastic conditions is described. When chemotherapeutic compounds and radiation activate NF-κB within cells, the cells are more resistant to the cytotoxic effects of these treatments. Inhibition of NF-κB activation is disclosed to provide a method to improve the efficacy of these cancer therapies.
11 Citations
20 Claims
-
1. A method of enhancing the cytotoxic effects of an antineoplastic chemotherapeutic agent, comprising administering to a mammalian subject in need of said antineoplastic chemotherapeutic agent a therapeutically effective amount of NF-κ
- B inhibitor in conjunction with the administration of a dosage of the chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent is increased compared to that which would occur in the absence of NF-κ
B inhibitor,wherein said NF-κ
B inhibitor is a proteasome inhibitor,wherein the dosage of said antineoplastic chemotherapeutic agent is decreased as compared to a dosage effective without administering the NF-κ
B inhibitor in conjunction with the administration of the chemotherapeutic agent,and wherein said subject is afflicted with lung, breast, prostate, brain, kidney, liver, spleen, pancreas, bone or muscle cancer, leukemia or lymphoma, a sarcoma, a carcinoma or a mixed tumor. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
- B inhibitor in conjunction with the administration of a dosage of the chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent is increased compared to that which would occur in the absence of NF-κ
Specification